Drug Discovery

QIAGEN and NVIDIA are combining QIAGEN Digital Insights with NVIDIA BioNeMo and graph-based AI to speed target ID, biomarker discovery and drug repurposing.

Isomorphic Labs raised $2.1 billion to scale its IsoDDE AI drug design engine. Backed by Thrive Capital, Alphabet, Temasek and the UK’s sovereign AI fund, the funding aims to speed therapeutic programs toward clinic.

How AI is moving from drug discovery into clinical trials, operations and commercial strategy, and why pharma must adopt a holistic, ecosystem view to win.

Insilico’s AI-discovered Rentosertib (ISM001-055) wins IND for inhalation Phase I in IPF, validating Pharma.AI’s faster, repeatable drug discovery approach.

Insilico Medicine convenes an industry-first Longevity Board to marry Big Pharma expertise with AI drug discovery, targeting dual-purpose therapies to extend healthspan.

Amazon’s AWS Bio Discovery pairs foundation models, agentic assistants and CRO wet labs to accelerate early-stage drug discovery for pharma and biotech.

Explore how AI-native Electronic Lab Notebooks convert record-keeping into proactive research assistance, integrating tools and data to accelerate drug discovery.

Latest on Verily’s $300M raise, Latent Labs’ Latent-X2, Insilico’s PandaClaw, and BMS-insitro ALS work. What these moves mean for AI-driven drug discovery.

EMA and FDA publish joint principles for safe AI across the medicines lifecycle, guiding risk-based validation, data governance, human oversight and patient safety.